ASAnastasiya Aleksandrovna Semenova

Anastasiya Aleksandrovna Semenova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasiya Aleksandrovna Semenova has a total of 294 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multiple myeloma: plasma cell immunophenotype and monitoring of minimal residual disease after induction therapy and autologous hematopoietic stem cell transplantation

    by Natalya A. Kupriyshina, Купрышина Н. А., Svetlana V. Chulkova, Чулкова Светлана Васильевна, Anastasiya A. Semenova, Семенова А. А., Olga P. Kolbatskaya, Колбацкая О. П., Gayane S. Tumyan, Тумян Г. С., et al.

    Background. Minimal residual disease (MRD) is the presence of a tumor clone in the bone marrow that can prevent remission during treatment. The immunophenotype of MM cells may be different, so it is necessary to understand the spectrum of markers that allow differentiating abnormal plasma cells (PCs). Monitoring MRD can influence the choice of patient management tactics. Aim. Analysis of the immunophenotype of myeloma cells and assessment of the frequency of MRD during treatment. Materials and methods. The study included 56 MM patients, the average age was 55 years. Induction chemotherapy was carried out according to the VRD scheme (including lenalidomide, bortezomib, and dexamethasone), autologous hematopoietic stem cell transplantation (auto-HSCT). The MOB status was assessed by multicolored flow cytometry using a Becton Dickinson FACSCanto II cytofluorimeter (Becton Diskinson, USA), Kaluza Analysis v. 2.1 (Beckman Coulter, Inc., USA). Monoclonal antibodies of clusters of differentiation (CD) were used: CD45, CD19, CD27, CD56, CD28, CD38, CD117, CD19, CD81, immunoglobulin light chains κ / λ, nuclear dye 7-aminoactinomycin D (Becton Diskinson, USA). Results. The most common MM immunophenotype was aberrant in the absence of CD19 and CD27, reduced expression of CD38, and abnormal presence of CD56 was noted. There is aberrancy in CD27 / CD117 / CD81. Most often, the immunophenotype of PCs corresponded to CD19–CD45–CD56+, noted in 46.4 % of cases. The frequency of MRD negativity after induction therapy is 35.7 %, after auto-HSCT – 56.7 %. A 1.3-fold decrease in the number of PCs in the bone marrow after auto-HSCT was established. Conversion after auto-HSCT of MRD positive cases (before transplantation of PCs more than 0.01 %, but less than 0.1 %) was detected in 53 % of patients. Conclusion. The MRD status in MM is assessed based on the aberrant expression of the main and additional plasma cell markers. At the stage of induction therapy and after auto-HSCT, the MRD status differs and there is a conversion of MRD-positive cases to negative ones. Monitoring MRD can be useful for choosing the tactics of managing patients with MM.

  • Open Access

    Real-World Outcomes of Glofitamab therapy in CAR-T naïve Patients with Relapsed/Refractory Large B-cell lymphoma

    by Liudmila Fedorova, Natalia Mikhailova, Kirill Lepik, Vladislav Markelov, Andrey Chekalov, Olesya Smykova, Gayane Tumyan, Anastasia Semenova, Arman Arakelyan, Lev Butaev, et al.

  • Open Access

    Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice

    by Anastasiya Aleksandrovna Semenova, G. S. Tumyan, Yu. V. Ermakova, A. S. Chuprakova, A. P. Chernova, M. V. Frolova, N. B. Mikhailova, L. V. Fedorova, O. D. Serdyuk, S. V. Samarina, et al.

    BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.

  • Open Access

    Results of a Double-Blind Prospective Comparative Randomized Phase 3 Clinical Trial of the Efficacy and Safety of BCD-264 and Darzalex as Monotherapy for Relapsed/Refractory Multiple Myeloma (BCD-264-2/DARVIVA)

    by T. V. Shelekhova, J. Kumar, S. J. Apte, Iu. S. Osipov, E. N. Misyurina, V. A. Doronin, T. S. Konstantinova, B. A. Bakirov, A. V. Proidakov, A. L. Uss, et al.

    AIM. To confirm the comparability of the biosimilar daratumumab BCD-264 (BIOCAD) with the reference drug Darzalex (Johnson & Johnson) in terms of efficacy and safety of the monotherapy for relapsed/refractory (r/r) multiple myeloma (MM). MATERIALS & METHODS. This paper is based on the double-blind prospective comparative randomized phase 3 clinical trial BCD-264-2/DARVIVA assessing the efficacy and safety of BCD-264 and Darzalex as monotherapy for r/r MM. Duration of the blind period was 24 weeks. The trial enrolled 252 r/r MM patients treated with proteasome inhibitors and immunomodulatory drugs. This paper documents the analysis of the data collected within the blind period when the therapy was administered to Group 1 and Group 2, whereby neither the investigators nor the patients knew which drug is being used in each of the groups. RESULTS. The primary end point of the study was overall response rate (ORR) in 24 weeks after therapy onset. In Group 1, ORR was 36.2 % and it was 32.0 % in Group 2; ORR ratio for Group 1/2 was 1.13 (95% confidence interval [95% CI] 0.80–1.60) and 0.88 (95% CI 0.63–1.24) for Group 2/1. This confirmed the hypothesis of BCD-264 being no less effective than Darzalex. Besides, an additional hypothesis of drug equivalence was proved true demonstrating also the comparability of the drugs across all secondary efficacy end points and safety parameters. The most common adverse events reported in both groups were leukopenia, neutropenia, lymphopenia, anemia, thrombocythemia, infusion-associated reactions, and pneumonia. CONCLUSION. Both drugs BCD-264 and Darzalex showed comparable efficacy and safety during the 24-week period in the BCD-264-2/DARVIVA trial as well as comparable immunogenicity and pharmacokinetic profile.


  • Open Access

    Primary Central Nervous System Lymphoma: A Literature Review, Diagnosis, Treatment, and Prognosis

    by Selmi Faikovna Ramazanova, A. V. Arakelyan, A. A. Semenova, O. Yu. Baranova, D. N. Tupitsyna, M. Yu. Kichigina, O. P. Trofimova, G. D. Petrova, A. S. Subbotin, V. O. Shpirko, et al.

    BACKGROUND. Primary lymphoma of the CNS (PLCNS) is one of the rare extranodal lymphoid tumors, which, in the vast majority of cases, is represented by diffuse large B-cell lymphoma (DLBCL). Tumor location, poor performance status with frequent neurological deficits as well as elderly age of the majority of patients restrict the opportunities for both diagnosis and treatment of this disease. AIM. To study the clinical manifestations and chemotherapy options for patients with newly diagnosed PLCNS. MATERIALS & METHODS. This study was based on the clinical data from 29 PLCNS patients treated at the Drug Chemotherapy and Hematology Department of the NN Blokhin National Medical Cancer Research Center from 2020 to 2025. The median age was 57 years (range 34–71 years), 35 % of patients were over 60 years of age, there were 16 (55 %) men. On presentation, more than a half of patients (n = 18; 62 %) had poor performance status (ECOG > 2). By immunohistochemical analysis, DLBCL was diagnosed in all patients: in 22 cases stereotactic biopsy was performed to verify the diagnosis, whereas in 7 cases open surgery was needed. An absolute majority of patients (n = 26; 90 %) received high-dose methotrexate (3–3.5 g/m2) as part of various combined regimens: R-MVT in 19 (66 %), R-MVР in 2 (7 %), R2-MV in 4 (14 %), and R-МAra-C in 1 (3 %) cases. Those 14 (48 %) patients who achieved antitumor effect after 2–4 cycles underwent consolidation in the form of external beam radiation therapy (n = 6; 21 %) or high-dose chemotherapy (n = 8; 28 %) with autologous hematopoietic stem cell transplantation (auto-HSCT). Maintenance therapy with temozolomide or lenalidomide was administered to 10 (35 %) patients. RESULTS. With the median follow-up of 13 months, the 2-year progression-free survival (PFS) was 34.5 % (median 9 months), and the 2-year overall survival (OS) was 54.3 % (median 35 months). The most important prognostic factor was achievement of complete remission (CR): the median PFS in patients with CR was 17 months vs. 2 months in patients without it, the median OS was 35 months and 5 months, respectively. Consolidation therapy, regardless of the method used (radiation therapy or auto-HSCT), also considerably improved the rates of long-term survival: the 2-year PFS was 55.1 % vs. 9.7 % without consolidation, the 2-year OS was 79.5 % and 30.5 %, respectively. CONCLUSION. PLCNS is characterized by a highly aggressive course. Administration of methotrexate-based regimens combined with alkylating or immunomodulatory agents followed by consolidation therapy is associated with improved rates of long-term survival. The results of first-line therapy present a key factor in determining the outcome of the disease, since the available treatment options for relapsed/refractory tumors of this kind are extremely limited and hardly effective.

  • Open Access

    Efficacy and Tolerability of the PET-Guided Program BrECADD for Advanced Stages of Classical Hodgkin Lymphoma: Data from the Real-World Setting in Russia

    by Elena Andreevna Demina, O. S. Samoilova, A. V. Halturin, O. M. Malchuk, V. O. Sarzhevskiy, A. A. Samoylova, G. S. Tumyan, A. A. Semenova, A. F. Saidullaeva, K. D. Kaplanov, et al.

    BACKGROUND. In 2024, the German Hodgkin Study Group (GHSG) published the unprecedented results of the HD21 trial on PET-guided program BrECADD for patients with advanced stages of classical Hodgkin lymphoma (cHL) showing the highest cure probability with the best tolerability. AIM. To review and analyze the first experience in Russia with BrECADD administered to patients with advanced stages of cHL in a real-world setting. MATERIALS & METHODS. Clinical data from 20 BrECADD recipients with advanced stages of newly diagnosed cHL were provided by 5 medical institutions from 3 cities in Russia. The median age was 31.5 years (range 19–43 years), there were 13 (65 %) female patients. PET/CT after 2 cycles (PET-2) was performed in 9 patients, 6 (66.6 %) of them showed complete metabolic response, which is similar to the results of the HD21 trial (64 %). PET-guided therapy was administered to only 5 patients (25 %), while in the rest of them the number of BrECADD cycles was determined by the attending physician regardless of whether an interim PET-2 was performed and irrespective of its results: 16 patients received 4 and 4 patients received 6 BrECADD cycles. Consolidating radiotherapy was administered to 4 cHL patients. RESULTS. After the chemotherapy stage, complete metabolic response was achieved in 16 (84 %) out of 19 patients (1 patient in clinical remission refused PET after chemotherapy completion), which is similar to the results of the HD21 trial (82 %), partial remission was identified in 1 and disease progression was observed in 2 patients. With the follow-up of 17.5 months, all patients were alive, progression-free survival was 90 % by that time. There were no cases of cycle or dose reduction due to adverse events. Increasing the intervals between cycles in 1/3 patients did not affect general therapy outcomes. CONCLUSION. The analysis of the first findings on BrECADD demonstrated its high efficacy, moderate toxicity, and feasibility in a real-world setting in Russia. The main issue appeared to be non-compliance with the HD21 recommendations in the majority of cases, that requires further standardization in the implementation of the program with a view to establishing best practices and identifying lessons learned with BrECADD administration in the routine practice of treating advanced cHL stages.

  • Open Access

    Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program

    by Liudmila Valerevna Fedorova, N. B. Mikhailova, K. V. Lepik, A. M. Chekalov, O. G. Smykova, V. V. Markelov, G. S. Tumyan, A. A. Semenova, A. V. Arakelyan, L. S. Butaev, et al.

    BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.

  • Open Access

    First experience with Isatuximab in newly diagnosed multiple myeloma patients. Case report

    by Anastasiya A. Semenova, Nikita O. Zemlyakov, Stanislav S. Kamyshanov, Alena I. Cherencova, Alexey S. Subbotin, Gayane S. Tumyan, Olga Yu. Baranova, Anna M. Stroganova, Arman V. Arakelyan

    Multiple myeloma (MM) is a clonal malignant lymphoproliferative disease with a continuously recurrent course. There has been a significant evolution of approaches to MM therapy, including the use of new induction regimens with not three, but four drugs with different mechanisms of action. This approach applies to patients both eligible and non-eligible for autologous hematopoietic stem cell transplantation (auto-HSCT). Thus, an international randomized clinical trial has shown the efficacy and safety of adding isatuximab (an anti-CD38 monoclonal antibody) to triplet therapy in patients with newly diagnosed MM. The publication presents two authors’ clinical cases of the use of the Isa-VRd induction regimen in patients with newly diagnosed MM. In a 61-year-old patient to undergo auto-HSCT (transplantation is not scheduled as initial therapy), after 4 induction cycles with Isa-VRd regimen, the combined positron-emission and X-ray computed tomography showed a pronounced decrease in the metabolic activity of tumor tissue, a negative status of minimal residual disease was achieved with the sensitivity of the NGF (next generation flow) method of 10⁻⁵; currently, maintenance therapy is ongoing. In a 63-year-old patient, a candidate for auto-HSCT, after completing 3 cycles of induction therapy with Isa-VRd quadruplet and an auto-HSCT, strict complete remission of the disease was achieved according to the International Myeloma Working Group (IMWG) 2016 criteria. Maintenance therapy is currently ongoing.

  • Open Access

    Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: A Literature Review and Our Own Experience

    by Ulyana Gordeevna Koshkina, A. A. Semenova, M. Yu. Kichigina, D. N. Tupitsyna, V. O. Shpirko, A. I. Cherencova, S. F. Ramazanova, N. O. Zemlyakov, I. Z. Zavodnova, A. V. Arakelyan, et al.

    AIM. To assess the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKi) as first and subsequent lines of mantle cell lymphoma (MCL) therapy. MATERIALS & METHODS. This study enrolled 30 patients with newly diagnosed (ndMCL; n = 17) and relapsed/refractory MCL (r/r MCL; n = 13) treated with BTKi at the Drug Chemotherapy and Hematology Department of the NN Blokhin National Medical Cancer Research Center during 2016–2025. NdMCL patients less than 60 years of age (n = 10/17; 58 %) were treated with alternating regimen R-CHOP + I/R-DHAOx combined with BTKi, 6 of them received high-dose chemotherapy with autologous hematopoietic stem cell transplantation. Elderly ndMCL patients (n = 7/17; 41 %) were treated with R-B program combined with BTKi. Irrespective of the induction phase, rituximab maintenance therapy (3 years) and BTKi (2 years) were administered to all patients. For the treatment of r/r MCL, BTKi was used as a monoregimen in 6 (46 %) patients, 2 (15 %) patients received it in combination with R-B, and 5 (38 %) in combination with rituximab. RESULTS. With the median follow-up of 36 months, ndMCL patients (n = 17) showed the 3-year progression-free survival (PFS) of 81.4 % and the 3-year overall survival (OS) of 84.4 %. In the r/r MCL group, with the median follow-up of 22 months, the 3-year PFS was 60.9 %, and the 3-year OS was 67 %. During this time, in the period from 3 to 23 months, 3 patients died (2 of them due to disease progression and 1 died from an infection). Toxicity profile of BTKi combination appeared to be manageable, whereas more infectious complications (53.8 % vs. 35.3 %) and more cases of pneumonia (53.8 vs. 29.4 %) were observed in r/r MCL vs. ndMCL patients. CONCLUSION. The administration of BTKi combined with chemotherapy is associated with high efficacy and favorable toxicity profile in the treatment of both ndMCL and r/r MCL.

  • Open Access

    The Prognostic Value of Positron Emission Tomography Findings in the Treatment of Primary Mediastinal (Thymic) Large B-Cell Lymphoma

    by A. S. Subbotin, Arman Vachakanovich Arakelyan, G. S. Tumyan, V. V. Solomyanyi, B. M. Khakulova, A. A. Semenova, M. Yu. Kichigina, I. Z. Zavodnova, V. O. Shpirko, Yu. I. Klyuchagina, et al.

    BACKGROUND. Combined positron emission tomography/computed tomography (PET-CT) with [18F]fluorodeoxyglucose is an essential instrument of monitoring the response to chemotherapy in primary mediastinal (thymic) large B-cell lymphoma (PMBCL). Of outstanding interest is the interpretation of PET-CT findings with respect to the frequent persistence of large residual mediastinal tumor after the end of drug therapy in PMBCL patients. AIM. To assess the prognostic value of PET-CT findings at different treatment stages in patients with newly diagnosed PMBCL. MATERIALS & METHODS. This study is based on the clinical data from 28 PMBCL patients (altogether, 131 patients are followed-up) who were treated with R-DA-EPOCH ± radiotherapy at the NN Blokhin National Medical Cancer Research Center from 2011 to 2024. The median age was 35 years (range 21–48 years), most patients were women (n = 23; 82 %). This group of patients was selected because of the availability of PET-CT data to be closely analyzed prior to treatment, after 3 cycles (interim PET-CT), and by the end of the drug stage. This paper focuses on the data of 20 PMBCL patients including not only Deauville criteria (DC) for response but also the following technically determinable volumetric parameters: total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), as well as standardized uptake values (SUVmax, SUVpeak, ΔSUVmax, ΔSUVpeak, and rSUVmax), maximum diameter (Dmax and ΔDmax), and products of perpendicular lesion diameters (PD, ΔPD). RESULTS. With a 23-month median follow-up, the 2-year progression-free survival (PFS) in the total group was 78.6 % whereas the 2-year overall survival was 100 %. Incomplete metabolic response (DC 4–5) was reported in 19 (68 %) patients by the interim PET-CT and in 15 (54 %) patients by the end-of-treatment PET-CT. At the same time, the prognosis in patients with DC 4 and DC 5 was markedly different, but the 2-year PFS in the groups with complete (DC 1–3) and partial (DC 4) metabolic response appeared to be identical and accounted for 85 %. Moreover, all patients with DC 5 showed disease progression after chemotherapy. In PMBCL, two volumetric parameters (TMTV and TLG) have a particularly high prognostic value: the 2-year PFS in the group with high and low TMTV was 40 % and 93 %, respectively, and with high and low TLG it was 57 % and 92 %, respectively. CONCLUSION. PET-negative status (DC 1–3) confirmed already by the interim analysis is a reliable factor for favorable prognosis in PMBCL. After completing drug therapy, a considerable proportion of patients show incomplete metabolic response (DC 4–5). However, long-term survival rates corresponding to DC 4 are noninferior to those in patients with DC 1–3, whereas in patients with DC 5, they are considerably worse. High TMTV and TLG values prior to chemotherapy are associated with unfavorable course of the disease.